Exhibit 99.1

LOGO

 

Interim Condensed

Consolidated Financial Statements (unaudited)

(Expressed in thousands of United States (U.S.) dollars)

Aurinia Pharmaceuticals Inc.


Aurinia Pharmaceuticals Inc.

Interim Condensed Consolidated Statements of Financial Position

(Unaudited)

 

(Expressed in thousands of U.S. dollars)

 

    

June 30,

2015

$

   

December 31

2014

$

 

Assets

    

Current assets

    

Cash and cash equivalents

     15,728        22,706   

Short term investment (note 4)

     10,008        9,998   

Accounts receivable

     85        92   

Prepaid expenses

     464        755   
  

 

 

   

 

 

 
     26,285        33,551   

Non-current assets

    

Property and equipment

     47        52   

Acquired intellectual property and other intangible assets

     17,765        18,489   

Prepaid deposits

     286        286   
  

 

 

   

 

 

 

Total assets

     44,383        52,378   
  

 

 

   

 

 

 

Liabilities and Shareholders’ Equity

    

Current liabilities

    

Accounts payable and accrued liabilities

     3,351        2,464   

Current portion of deferred revenue

     217        217   

Provision for restructuring costs

     155        155   
  

 

 

   

 

 

 
     3,723        2,836   

Non-current liabilities

    

Deferred revenue

     738        847   

Provision for restructuring costs

     39        116   

Contingent consideration (note 5)

     3,746        3,473   

Derivative warrant liability (note 6)

     8,124        11,235   
  

 

 

   

 

 

 
     16,370        18,507   
  

 

 

   

 

 

 

Shareholders’ equity

    

Share capital

    

Common shares (note 7)

     261,546        259,712   

Warrants (note 7)

     1,297        1,804   

Contributed surplus

     14,455        12,306   

Accumulated other comprehensive loss

     (805     (805

Deficit

     (248,480     (239,146
  

 

 

   

 

 

 

Total shareholders’ equity

     28,013        33,871   
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

     44,383        52,378   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.


Aurinia Pharmaceuticals Inc.

Interim Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(Expressed in thousands of U.S. dollars, except per share data)

 

     Three months ended     Six months ended  
    

June 30,

2015

$

   

June 30,

2014

$

(restated-
note 2)

   

June 30,

2015

$

   

June 30,

2014

$

(restated-
note 2)

 

Revenue

        

Licensing revenue

     29        29        59        59   

Research and development revenue

     25        25        50        50   

Contract services

     5        17        12        29   
  

 

 

   

 

 

   

 

 

   

 

 

 
     59        71        121        138   
  

 

 

   

 

 

   

 

 

   

 

 

 

Expenses

        

Research and development

     4,330        2,547        7,660        3,587   

Corporate, administration and business development

     1,414        1,713        3,319        4,086   

Amortization of acquired intellectual property and other intangible assets

     358        359        750        718   

Amortization of property and equipment

     5        10        11        20   

Contract services

     4        10        9        18   

Restructuring costs

     —          403        —          972   

Other expense (income) (note 8)

     83        (954     181        (55
  

 

 

   

 

 

   

 

 

   

 

 

 
     6,194        4,088        11,930        9,346   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss before gain (loss) on derivative warrant liability

     (6,135     (4,017     (11,809     (9,208

Gain (loss) on derivative warrant liability (notes 2 and 6)

     5,402        (7,017     2,475        (6,601
  

 

 

   

 

 

   

 

 

   

 

 

 

Net loss for the period

     (733     (11,034     (9,334     (15,809
  

 

 

   

 

 

   

 

 

   

 

 

 

Other comprehensive loss

        

Translation adjustment which will not be reclassified subsequently to loss

     —          —          —          (605
  

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss for the period

     (733     (11,034     (9,334     (16,414
  

 

 

   

 

 

   

 

 

   

 

 

 

Loss per share (note 9)

        

Basic and diluted net loss per common share

     (0.02     (0.35     (0.29     (0.59
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

2


Aurinia Pharmaceuticals Inc.

Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(Expressed in thousands of U.S. dollars)

 

    

Common
Shares

$

   

Warrants

$

   

Contributed

surplus

$

   

Accumulated
Other
Comprehensive
Loss

$

   

Deficit

$

   

Shareholders’

Equity

$

 

Balance – January 1, 2015

     259,712        1,804        12,306        (805     (239,146     33,871   

Exercise of warrants (note 7)

     1,020        (335     —          —          —          685   

Exercise of cashless warrants

     636        —          —          —          —          636   

Expiry of warrants

     —          (172     172        —          —          —     

Exercise of stock options (note 7)

     178        —          (80     —          —          98   

Stock-based compensation

     —          —          2,057        —          —          2,057   

Net loss for the period

     —          —          —          —          (9,334     (9,334
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance – June 30, 2015

     261,546        1,297        14,455        (805     (248,480     28,013   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance – January 1, 2014

     220,908        2,256        10,074        (200     (219,725     13,313   

Comprehensive loss for the period

     —          —          —          (605     —          (605

Issue of units (note 7)

     40,059        —          —          —          —          40,059   

Share issue costs (note 7)

     (2,844     —          —          —          —          (2,844

Exercise of warrants (note 7)

     226        (62     —          —          —          164   

Stock-based compensation

     —          —          1,733        —          —          1,733   

Net loss for the period

     —          —          —          —          (15,809     (15,809
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Balance – June 30, 2014

     258,349        2,194        11,807        (805     (235,534     36,011   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

3


Aurinia Pharmaceuticals Inc.

Interim Condensed Consolidated Statements of Cash Flow

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(Expressed in thousands of U.S. dollars)

 

     Three months ended     Six months ended  
    

June 30,

2015

$

   

June 30,

2014

$

(restated-
note 2)

   

June 30,

2015

$

   

June 30,

2014

$

(restated-
note 2)

 

Cash flow provided by (used in)

        

Operating activities

        

Net loss for the period

     (733     (11,034     (9,334     (15,809

Adjustments for:

        

Amortization of deferred revenue

     (54     (54     (109     (109

Amortization of property and equipment

     5        10        11        20   

Amortization of acquired intellectual property and other intangible assets

     358        359        750        718   

Revaluation of contingent consideration

     89        105        273        638   

Loss (gain) on derivative warrant liability

     (5,402     7,017        (2,475     6,601   

Gain on warrant liability

     —          (1,084     —          (1,084

Stock-based compensation

     773        435        2,057        1,733   

Change in provision for restructuring costs

     (38     177        (77     277   

Share issue costs allocated to warrant liability

     —          —          —          203   

Gain on disposal of property and equipment

     —          —          —          (1
  

 

 

   

 

 

   

 

 

   

 

 

 
     (5,002     (4,069     (8,904     (6,813

Net change in other operating assets and liabilities (note 11)

     1,305        (114     1,185        (2,723
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in operating activities

     (3,697     (4,183     (7,719     (9,536
  

 

 

   

 

 

   

 

 

   

 

 

 

Investing activities

        

Increase in short-term investment

     (9     —          (10     —     

Purchase of equipment

     (1     (44     (6     (44

Proceeds on disposal of property and equipment

     —          —          —          1   

Capitalized patent costs

     (21     (3     (26     (4
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

     (31     (47     (42     (47
  

 

 

   

 

 

   

 

 

   

 

 

 

Financing activities

        

Proceeds from exercise of warrants

     400        34        685        164   

Proceeds from exercise of stock options

     14        —          98        —     

Proceeds from issuance of units

     —          —          —          52,000   

Share issue costs related to issuance of units

     —          —          —          (3,693

Payment of financing milestone to ILJIN

     —          —          —          (1,600
  

 

 

   

 

 

   

 

 

   

 

 

 

Net cash generated from financing activities

     414        34        783        46,871   
  

 

 

   

 

 

   

 

 

   

 

 

 

Effect of exchange rate adjustment on cash and cash equivalents

     —          —          —          (16
  

 

 

   

 

 

   

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents

     (3,314     (4,196     (6,978     37,272   

Cash and cash equivalents – beginning of period

     19,042        43,289        22,706        1,821   
  

 

 

   

 

 

   

 

 

   

 

 

 

Cash and cash equivalents – end of period

     15,728        39,093        15,728        39,093   
  

 

 

   

 

 

   

 

 

   

 

 

 

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

 

4


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

1. Corporate information

Aurinia Pharmaceuticals Inc. or the “Company” is a clinical stage pharmaceutical company with its head office located at #1203-4464 Markham Street, Victoria, British Columbia V8Z 7X8 where clinical, regulatory and business development functions of the Company are conducted. The Company has its registered office located at #201, 17904-105 Avenue, Edmonton, Alberta T5S 2H5 where the finance function is performed.

Aurinia Pharmaceuticals Inc. is organized pursuant to the Business Corporations Act (Alberta). The Company’s Common Shares are currently listed and traded on the NASDAQ Global Market (NASDAQ) under the symbol AUPH and on the Toronto Stock Exchange under the symbol AUP. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.

These interim condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma Corp., Aurinia Pharmaceuticals, Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated).

These interim condensed consolidated financial statements were authorized for issue by the audit committee of the Board of Directors on August 10, 2015.

 

2. Revision of prior period comparatives for correction of accounting for warrants

As described in note 6, the Offering completed by the Company on February 14, 2014, resulted in the issuance of 4,729,843 warrants, exercisable for a period of five years from the date of issuance at an exercise price of $3.22 per warrant. The holders of the warrants may elect, in lieu of exercising the warrants for cash, a cashless exercise option to receive common shares equal to the fair value of the warrants based on the number of warrants to be exercised multiplied by a five day weighted average market price less the exercise price, with the difference divided by the weighted average market price. If a warrant holder exercises this option, there will be variability in the number of shares issued per warrant.

A review of the application of IFRS to these previously issued warrants has resulted in a revision of prior period comparatives for restatement of our previous accounting for the warrants.

In accordance with IFRS, a contract to issue a variable number of shares fails to meet the definition of equity and must instead be classified as a derivative liability and measured at fair value with changes in fair value recognized in the statement of operations and comprehensive loss at each period end. The derivative liability will ultimately be converted to the Company’s equity (common shares) when the warrants are exercised, or will be extinguished upon the expiry of the outstanding warrants, and will not result in the outlay of any cash by the Company.

In the original accounting determination, the estimated fair value of the warrants was recorded in equity at $10,418,000, offset by an allocation of issuance costs of $739,000. At initial recognition the Company should have recorded the estimated fair value of the warrants as a derivative warrant liability at $9,107,000, with allocated issuance costs of $646,000 recognized as other expense. In addition, at March 31, 2014, based on the trading price of the Company’s shares at that time, the Company should have adjusted the estimated fair value of the derivative warrant liability to $8,045,000, resulting in a gain on revaluation of derivative warrant liability in “Other expense (income)” for the three months ended March 31, 2014 of $1,062,000. At June 30, 2014, based on the trading price of the Company’s shares at that time, the Company should have adjusted the estimated fair value of the derivative warrant liability to $15,062,000, resulting in a loss on revaluation of derivative warrant liability of $7,017,000 in “Other expense (income)” for the three months ended June 30, 2014. At September 30, 2014, based on the trading price of the Company’s shares at that time, the Company should have adjusted the estimated fair value of the derivative warrant liability to $9,794,000, resulting in a gain on revaluation of derivative warrant liability of $5,268,000 in “Other expense (income)” for the three months ended September 30, 2014.

There was no impact on cash from operating, financing or investing activities.

 

5


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

The following table illustrates the impact of the correction for the relevant quarters:

Balance Sheet:

 

     As at March 31, 2014  
     As previously
reported
$
     Adjustment
$
     As revised
$
 

Derivative warrant liability

     —           8,045         8,045   

Equity

        

Common shares

     257,084         1,218         258,302   

Warrants

     11,886         (9,679      2,207   

Deficit

     (224,916      416         (224,500
  

 

 

    

 

 

    

 

 

 
     As at June 30, 2014  
     As previously
reported
$
     Adjustment
$
     As revised
$
 

Derivative warrant liability

     —           15,062         15,062   

Equity

        

Common shares

     257,131         1,218         258,349   

Warrants

     11,873         (9,679      2,194   

Deficit

     (228,933      (6,601      (235,534
  

 

 

    

 

 

    

 

 

 
     As at September 30, 2014  
     As previously
reported
$
     Adjustment
$
     As revised
$
 

Derivative warrant liability

     —           9,794         9,794   

Equity

        

Common shares

     257,790         1,218         259,008   

Warrants

     11,691         (9,679      2,012   

Deficit

     (231,453      (1,333      (232,786
  

 

 

    

 

 

    

 

 

 
Comprehensive loss:   
     Three months ended March 31, 2014  
     As previously
reported
$
     Adjustment
$
     As revised
$
 

Gain (loss) on revaluation of derivative warrant liability

        

Revaluation adjustment on derivative warrant liability

     —           1,062         1,062   

Share issue costs allocated to derivative warrant liability

     —           (646      (646
  

 

 

    

 

 

    

 

 

 
     —           416         416   
  

 

 

    

 

 

    

 

 

 

Comprehensive loss

     (5,796      416         (5,380

Basic and diluted net loss per common share

     (0.24      (0.02      (0.22
  

 

 

    

 

 

    

 

 

 

 

     Three months ended June 30, 2014     Six months ended June 30, 2014  
     As
previously
reported
$
    Adjustment
$
    As
revised
$
    As previously
reported
$
    Adjustment
$
    As
revised
$
 

Gain (loss) on revaluation of derivative warrant liability

            

Revaluation adjustment on derivative warrant liability

     —          (7,017     (7,017     —          (5,955     (5,955

Share issue costs allocated to derivative warrant liability

     —          —          —          —          (646     (646
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     —          (7,017     (7,017     —          (6,601     (6,601
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Comprehensive loss

     (4,017     (7,017     (11,034     (9,813     (6,601     (16,414

Basic and diluted net loss per common share

     (0.13     (0.22     (0.35     (0.35     (0.24     (0.59
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

6


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

     Three months ended September 30, 2014      Nine months ended September 30, 2014  
     As
previously
reported
$
    Adjustment
$
     As
revised
$
     As
previously
reported
$
    Adjustment
$
    As
revised
$
 

Gain (loss) on revaluation of derivative warrant liability

              

Revaluation adjustment on derivative warrant liability

     —          5,268         5,268         —          (687     (687

Share issue costs allocated to derivative warrant liability

     —          —           —           —          (646     (646
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 
     —          5,268         5,268         —          (1,333     (1,333
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Comprehensive income (loss)

     (2,520     5,268         2,748         (12,333     (1,333     (13,666

Basic income (loss) per common share

     (0.08     0.17         0.09         (0.41     (0.05     (0.46

Diluted income (loss) per common share

     (0.08     0.16         0.08         (0.41     (0.05     (0.46
  

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

3. Basis of presentation

These interim condensed consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as applicable to interim financial reports including IAS 34, Interim Financial Reporting, and should be read in conjunction with the annual restated financial statements of the Company for the year ended December 31, 2014 which have been prepared in accordance with IFRS, as issued by the International Accounting Standards Board (“IASB”).

 

4. Short term investment

The short term investment, which is recorded at amortized cost is a HSBC Bank U.S. denominated discount note with a face value of $10,010,000 and a cost of $10,008,000. The note, purchased on February 4, 2015, matures on August 4, 2015 and has an effective interest rate of 0.218%. The Company, on maturity, renewed the discount note for a term of 180 days at an interest rate of 0.31%.

 

5. Contingent consideration

The Company has recorded the fair value of contingent consideration payable to ILJIN Life Science Co., Ltd. (“ILJIN”) resulting from the Arrangement Agreement completed on September 20, 2013 between the Company, Aurinia Pharma Corp. and ILJIN.

Contingent consideration includes potential payments of up to $10,000,000 to be paid in five equal tranches according to the achievement of pre-defined clinical and marketing milestones.

The fair value of this portion of contingent consideration at June 30, 2015 was estimated to be $3,746,000 (December 31, 2014—$3,473,000) and was determined by applying the income approach. The fair value estimates at June 30, 2015 were based on a discount rate of 10% and an assumed probability-adjusted payment range between 35% and 70%. This is a level 3 recurring fair value measurement. There have been no changes in the assumptions since December 31, 2014.

 

6. Derivative warrant liability

On February 14, 2014, the Company completed a $52,000,000 private placement (the Offering). Under the terms of the Offering, the Company issued 18,919,404 units (the Units) at a subscription price per Unit of $2.7485, each Unit consisting of one common share and one-quarter (0.25) of a common share purchase warrant (a Warrant), exercisable for a period of five years from the date of issuance at an exercise price of $3.2204. The holders of the Warrants issued pursuant to the February 14, 2014 private placement may elect, in lieu of exercising the Warrants for cash, a cashless exercise option to receive common shares equal to the fair value of the Warrants based on the number of Warrants to be exercised multiplied by a five day weighted average market price less the exercise price with the difference divided by the weighted average market price. If a Warrant holder exercises this option, there will be variability in the number of shares issued per Warrant.

In accordance with IFRS, a contract to issue a variable number of shares fails to meet the definition of equity and must instead be classified as a derivative liability and measured at fair value with changes in fair value recognized in the statement of operations and comprehensive loss at each period end. The derivative liability will ultimately be converted to the Company’s equity (common shares) when the Warrants are exercised, or will be extinguished upon the expiry of the outstanding Warrants, and will not result in the outlay of any cash by the Company.

 

7


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

In the first quarter ended March 31, 2015, a holder of these Warrants elected this option and the Company issued 66,000 common shares upon the cashless exercise of 182,000 Warrants. These Warrants had a fair value of $636,000 at the date of exercise, determined using the Black-Scholes warrant pricing model. This amount was transferred from derivative warrant liability to common shares.

At June 30, 2015 the Company recorded a derivative warrant liability at $8,124,000 (June 30, 2014 - $15,062,000) which resulted in a gain on revaluation of derivative warrant liability for the three months ended June 30, 2015 of $5,402,000 related to the 4,548,000 derivative liability warrants (June 30, 2014 - loss on revaluation of derivative warrant liability of $7,017,000).

The Company considers expected volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the Warrants was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term.

The Company uses the Black-Scholes option pricing model to estimate fair value. The following weighted average assumptions were used to estimate the fair value of the derivative warrant liability on June 30, 2015 and June 30, 2014:

 

    

June 30,

2015

   

June 30,

2014

 

Annualized volatility

     84     85

Risk-free interest rate

     1.11     1.47

Expected life of warrants in years

     3.62        4.62   

Dividend rate

     0.0     0.0

Market price

     3.10        4.50   

Fair value per Warrant

     1.79        3.19   

This is a Level 3 recurring fair value measurement. The key level 3 inputs used by management to determine the fair value are the market price and the expected volatility. If the market price were to increase by a factor of 10% this would increase the obligation by approximately $1,124,000 at June 30, 2015. If the market price were to decrease by a factor of 10% this would decrease the obligation by approximately $1,098,000. If the volatility were to increase by 10%, this would increase the obligation by approximately $631,000. If the volatility were to decrease by 10%, this would decrease the obligation by approximately $673,000 at June 30, 2015.

The following table presents the changes in the derivative warrant liability categorized as Level 3:

 

     # of Warrants
(in thousands)
     $  

Balance at January 1, 2015

     4,730         11,235   

Conversion to equity (common shares) upon exercise of warrants

     (182      (636

Loss on revaluation of derivative warrant liability

     —           2,927   
  

 

 

    

 

 

 

Balance at March 31, 2015

     4,548         13,526   

Gain on revaluation of derivative warrant liability

     —           (5,402
  

 

 

    

 

 

 

Balance at June 30, 2015

     4,548         8,124   
  

 

 

    

 

 

 

Balance at January 1, 2014

     —           —     

February 14, 2014 issuance of warrants

     4,730         9,107   

Gain on revaluation of derivative warrant liability

     —           (1,062
  

 

 

    

 

 

 

Balance at March 31, 2014

     4,730         8,045   

Loss on revaluation of derivative warrant liability

     —           7,017   
  

 

 

    

 

 

 

Balance at June 30, 2014

     4,730         15,062   
  

 

 

    

 

 

 

 

8


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

7. Share Capital

 

(a) Common shares

Authorized

The Company is authorized to issue an unlimited number of common shares without par value.

 

     Common Shares  
Issued    #      $  
     (in thousands)      (restated-
note 2)
 

Balance at January 1, 2015

     31,818         259,712   

Issued pursuant to exercise of stock options

     35         178   

Issued pursuant to exercise of warrants

     348         1,020   

Issued pursuant to exercise of derivative liability warrants

     66         636   
  

 

 

    

 

 

 

Balance at June 30, 2015

     32,267         261,546   
  

 

 

    

 

 

 

Balance at January 1, 2014

     12,375         220,908   

Issued pursuant to February 14, 2014 Private Placement

     18,919         40,059   

Share issue costs related to Private placement

     —           (2,844

Issued pursuant to exercise of warrants

     75         226   
  

 

 

    

 

 

 

Balance at June 30, 2014

     31,369         258,349   
  

 

 

    

 

 

 

 

(b) Warrants

 

     Warrants  
Issued    #     $  
     (in thousands)     (restated-
note 2)
 

Balance at January 1, 2015

     1,724        1,804   

Warrants exercised

     (348     (335

Warrants expired

     (8     (172
  

 

 

   

 

 

 

Balance June 30, 2015

     1,368        1,297   
  

 

 

   

 

 

 

Balance at January 1, 2014

     2,318        2,256   

Warrants exercised

     (75     (62
  

 

 

   

 

 

 

Balance at June 30, 2014

     2,243        2,194   
  

 

 

   

 

 

 

The Company issued 348,000 common shares upon the exercise of 348,000 warrants for proceeds of $685,000. These warrants had a Black-Scholes calculated fair value of $335,000. This amount was transferred from warrants to common shares as a result of the exercise of the warrants.

 

9


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

Warrants outstanding at June 30, 2015   

#

(in thousands)

    

Weighted average
exercise price

$

 
Expiry date:      

Exercisable in CDN$

     

September 20, 2016 (CDN$2.25 and CDN$2.50)

     1,039         2.00   

June 26, 2018 (CDN$2.25 and CDN$2.50)

     315         2.00   

December 31, 2018 (CDN$2.00)

     14         1.60   
  

 

 

    

 

 

 
     1,368         1.99   

Exercisable in US$

     

February 14, 2019 (note 6)

     4,548         3.22   
  

 

 

    

 

 

 
     5,916         2.94   
  

 

 

    

 

 

 

 

(c) Stock options and compensation expense

The maximum number of Common Shares issuable under the Stock Option Plan is equal to 10% of the issued and outstanding Common Shares at the time the Common Shares are reserved for issuance. As at June 30, 2015 there were 32,267,000 Common Shares of the Company issued and outstanding, resulting in a maximum of 3,227,000 stock options available for issuance under the Stock Option Plan. An aggregate total of 2,399,000 options are presently outstanding, representing 7.4% of the issued and outstanding Common Shares of the Company.

The Stock Option Plan requires the exercise price of each option to be determined by the Board of Directors and not to be less than the closing market price of the Company’s stock on the day immediately prior to the date of grant. Any options which expire may be re-granted. The Board approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments.

A summary of the status of the Company’s stock option plan as of June 30, 2015 and 2014 and changes during the six month periods ended on those dates is presented below:

 

     June 30, 2015      June 30, 2014
(restated-
note 2)
 
     #     

Weighted

average

exercise

price

In CDN$

     #     

Weighted

average

exercise

price

In CDN$

 

Outstanding – Beginning of period

     1,376         3.92         276         5.04   

Granted

     1,068         4.70         1,192         3.50   

Expired

     —           —           (34      7.50   

Forfeited and cancelled

     (10      4.25         (14      4.77   

Exercised

     (35      3.50         —           —     
  

 

 

    

 

 

    

 

 

    

 

 

 

Outstanding – End of period

     2,399         3.96         1,420         3.69   
  

 

 

    

 

 

    

 

 

    

 

 

 

Options exercisable – End of period

     1,399         3.86         706         3.79   
  

 

 

    

 

 

    

 

 

    

 

 

 

On January 6, 2015, the Company granted 960,000 stock options to directors, officers and employees of the Company at a price of $3.59 (CDN$4.25) per common share. The options will vest periodically over a period of one year. The options are exercisable for a term of five years.

On April 7, 2015 the Company granted 48,000 stock options to employees of the Company at a price of $4.15 (CDN$5.19).

 

10


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

On June 2, 2015, the Company granted 60,000 stock options to the new directors appointed at the Annual General Meeting of Shareholders held on May 26, 2015, at a price of $3.47 (CDN$4.31).

The Company recognized stock-based compensation expense of $773,000 and $2,057,000 for the three and six months ended June 30, 2015 respectively (2014 – $435,000 and $1,733,000) with corresponding credits to contributed surplus. For the three and six month periods ended June 30, 2015, stock compensation expense has been allocated to research and development expense in the amount of $246,000 and $633,000 respectively, (2014 – $Nil and $Nil) and corporate administration expense in the amount of $527,000 and $1,424,000 (2014 – $435,000 and $1,480,000) and restructuring costs in the amount of $Nil and $Nil (2014 – $Nil and $253,000).

The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted to employees, officers and directors.

The following weighted average assumptions were used to estimate the fair value of the options granted during the six month periods ended June 30, 2015 and 2014:

 

    

June 30,

2015

   

June 30,

2014

 

Expected volatility

     85     85

Risk-free interest rate

     1.04        1.74   

Expected life of options in years

     3.9        7.1   

Estimated forfeiture rate

     11.9     11.9

Dividend rate

     0.0     0.0

Exercise price

     3.61        3.19   

Market price on date of grant

     3.61        3.19   

Fair value per common share option

     2.19        2.39   

The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behaviour.

Determining the fair value of stock options on grant date, requires judgment related to the choice of a pricing model, the estimation of stock price volatility and the expected term of the underlying instruments. Any changes in the estimates or inputs utilized to determine fair value could result in a significant impact on the Company’s reported operating results, liabilities or other components of shareholders’ equity. The key assumption used by management is the stock price volatility. If the stock price volatility was higher by a factor of 10% on the options granted during the six months ended June 30, 2015 this would have increased the stock compensation expense on options granted during this period by approximately $129,000. If the stock price volatility was lower by a factor of 10% on grant date this would have decreased the total stock compensation expense for the quarter by approximately $139,000.

 

11


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

8. Other expense (income)

 

     Three months ended      Six months ended  
    

June 30,

2015

$

    

June 30,

2014

$

(restated-

note 2)

    

June 30,

2015

$

     June 30,
2014 $
(restated-
note 2)
 

Other expense (income) net composed of:

           

Finance income

           

Interest income on short-term bank deposits

     (13      (22      (29      (32
  

 

 

    

 

 

    

 

 

    

 

 

 

Finance costs

           

Interest on drug supply loan

     —           —           —           30   
  

 

 

    

 

 

    

 

 

    

 

 

 

Other

           

Revaluation adjustment on contingent consideration (note 5)

     89         105         273         638   

Foreign exchange loss (gain)

     7         47         (63      191   

Share issue costs allocated to warrant liability

     —           —           —           203   

Gain on re-measurement of warrant liability

     —           (646      —           (646

Gain on extinguishment of warrant liability

     —           (438      —           (438

Gain on disposal of equipment

     —           —           —           (1
  

 

 

    

 

 

    

 

 

    

 

 

 
     96         (932      210         (53
  

 

 

    

 

 

    

 

 

    

 

 

 
     83         (954      181         (55
  

 

 

    

 

 

    

 

 

    

 

 

 

 

9. Net loss per common share

Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. In determining diluted net loss per common share, the weighted average number of common shares outstanding is adjusted for stock options and warrants eligible for exercise where the average market price of common shares for the three and six months ended June 30, 2015 exceeds the exercise price. Common shares that could potentially dilute basic net loss per common share in the future that could be issued from the exercise of outstanding stock options and warrants were not included in the computation of the diluted loss per common share for the three and six months ended June 30, 2015 and June 30, 2014 because to do so would be anti-dilutive.

The numerator and denominator used in the calculation of historical basic and diluted net loss amounts per common share are as follows:

 

     Three months ended      Six months ended  
     June 30,
2015

$
     June 30,
2014

$
(restated-
note 2)
     June 30,
2015

$
     June 30,
2014

$
(restated-
note 2)
 

Net loss for the period

     (733      (11,034      (9,334      (15,809
  

 

 

    

 

 

    

 

 

    

 

 

 
     #      #      #      #  
     In thousands      In thousands      In thousands      In thousands  

Weighted average common shares outstanding

     32,237         31,359         31,963         26,630   
  

 

 

    

 

 

    

 

 

    

 

 

 
     $      $      $      $  

Loss per common share (expressed in $ per share)

     (0.02      (0.35      (0.29      (0.59
  

 

 

    

 

 

    

 

 

    

 

 

 

 

12


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

The outstanding number and type of securities that would potentially dilute basic loss per common share in the future and which were not included in the computation of diluted loss per share, because to do so would have reduced the loss per common share (anti-dilutive) for the years presented, are as follows:

 

    

June 30,

2015

#

    

June 30,
2014

#

 
     In thousands      In thousands  

Stock options

     2,399         1,420   

Warrants (derivative liability)

     4,548         4,730   

Warrants (equity)

     1,368         2,243   
  

 

 

    

 

 

 
     8,315         8,393   
  

 

 

    

 

 

 

 

10. Segment disclosures

The Company’s operations comprise a single reporting segment engaged in the research, development and commercialization of therapeutic drugs. As the operations comprise a single reporting segment, amounts disclosed in the financial statements represent those of the single reporting unit. In addition, all of the Company’s long-lived assets are located in Canada.

The following geographic area data reflects revenue based on customer location.

Geographic information

 

     Three months ended      Six months ended  
    

June 30,

2015

$

    

June 30,

2014

$

    

June 30,

2015

$

    

June 30,

2014

$

 

Revenue

           

Canada

     30         42         62         79   

China

     29         29         59         59   
  

 

 

    

 

 

    

 

 

    

 

 

 
     59         71         121         138   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

11. Supplementary cash flow information

Net change in other operating assets and liabilities:

 

     Three months ended      Six months ended  
    

June 30,

2015

$

    

June 30,

2014

$

(restated-
note 2)

    

June 30,

2015

$

    

June 30,

2014

$

(restated-
note 2)

 

Accounts receivable

     29         (14      7         (12

Prepaid expenses and deposits

     (50      (1,407      291         (1,383

Accounts payable and accrued liabilities

     1,326         1,307         887         (131

Drug supply loan

     —           —           —           (1,197
  

 

 

    

 

 

    

 

 

    

 

 

 
     1,305         (114      1,185         (2,723
  

 

 

    

 

 

    

 

 

    

 

 

 

 

13


Aurinia Pharmaceuticals Inc.

Notes to Interim Condensed Consolidated Statements

(Unaudited)

For the three and six month periods ended June 30, 2015 and 2014

 

(amounts in tabular columns expressed in thousands of U.S. dollars)

 

12. Foreign exchange risk

The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates. Foreign currency risk is the risk that variations in exchange rates between the United States dollar, which is the Company’s functional currency, and foreign currencies, primarily with the Canadian dollar, will affect the Company’s operating and financial results.

The following table presents the Company’s exposure to the CDN dollar:

 

    

June 30,

2015

$

    

June 30,

2014

$

 

Cash and cash equivalents

     37         109   

Accounts receivable

     60         99   

Accounts payable and accrued liabilities

     (516      (1,103
  

 

 

    

 

 

 

Net exposure

     (419      (895
  

 

 

    

 

 

 
     Reporting Date Rate  
    

June 30,

2015

$

    

June 30,

2014

$

 

CDN$ - US$

     0.801         0.937   
  

 

 

    

 

 

 

Based on the Company’s foreign currency exposures noted above, varying the foreign exchange rates to reflect a ten percent strengthening of the U.S. dollar would have decreased the net loss by $42,000 assuming that all other variables remained constant. An assumed 10 percent weakening of the U.S. dollar would have had an equal but opposite effect to the amounts shown above, on the basis that all other variables remain constant.

 

14